News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Shares of Gilead Sciences (GILD) fell 2% on Wednesday following a Wall Street Journal report that the Trump administration is ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...